Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
Merck Sharp & Dohme LLC
Eisai Inc.
Checkpoint Therapeutics, Inc.
Gilead Sciences